

PRESS RELEASE 19th July 2010: Beremans Ltd announces publication of “Malaria vaccines: commercial prospects and landscape analysis”.

Beremans Ltd (www.beremans.com), the Cambridge (UK)-based provider of business intelligence services for the Life Sciences sector, announced today the publication of a report entitled ‘Malaria vaccines: commercial prospects and landscape analysis’. Dr. Nicholas Miller, MD of Beremans Ltd, said “Following the favourable reception of our analysis of the market landscape and commercial prospects for dengue vaccines, we have applied our models of international travel and developing country demographics to the malaria vaccine market. Malaria control and even eradication is of great importance, and interest in this field is reinforced by occasional high-profile cases of travel-associated malaria, such as Cheryl Cole. We have provided a uniquely detailed and up-to-date analysis of the malaria vaccine field, which is moving forward rapidly with the Phase 3 trials of GSK’s paediatric malaria vaccine. This report consolidates, extends and emphasises the franchise which Beremans has developed in providing market assessments for vaccines, including travel vaccines and vaccines for neglected diseases.”

As well as summarising the clinical/scientific state of knowledge regarding malaria, the >350-page report also provides an independent assessment of reported global incidence, independently generated estimates of actual global incidence, identification of the main technical challenges associated with malaria vaccine development, and analysis of major stakeholders and their influence on vaccine procurement and pricing. The main candidate malaria vaccines are discussed and analysed, pertinent clinical trials are summarised, and the main commercial and non-commercial parties interested in malaria vaccine development are outlined.

The report also presents relevant results from a major exercise to quantify the different populations that might be appropriate for malaria immunisation, namely total populations, women of child-bearing age (WOCBA), girls reaching child-bearing age (GRCBA), surviving infant populations; urban populations, urban WOCBA, urban GRCBA and urban infants; and travellers to regions of malaria transmission. For traveller populations, this required use of a detailed model using numerous manipulations, corrections and adjustments of raw travel data. This model provides defensible estimates of actual traveller numbers from each of 21 developed countries to each of >100 developing world countries. A Beremans model of developing country demographics was also used to forecast relevant population numbers to 2020, to provide a base for revenue projections. Importantly, the report identifies key data which lead to defensible assumptions for deriving malaria vaccine revenue projections. These assumptions (e.g. price, time of market entry, maximum market penetration, rate of market penetration, roll-out per country, etc.) are specified and justified in the text, and permit estimation of the market for hypothetical malaria vaccines in (i) the developed world private sector (i.e. a travel vaccine); (ii) the developing world private sector; and (iii) the developing world public sector. Finally, key experts in the malaria vaccine field were interviewed to obtain third-party views on aspects of the malaria vaccine market. Full transcripts of these interviews are provided in the report, which contains 55 figures, 87 tables and over 150,000 words. Dr. Miller said “In our opinion, we have the most comprehensive and accurate model of international travel available. We have applied this to, inter alia, the dengue vaccine market and the malaria vaccine market, but our model could be applied to any travel vaccine, or indeed to any product, medical or otherwise, aimed at residents in developed economies travelling to developing or emerging economies. It is a fundamental and valuable resource with very broad applicability.”

For further information please email:

Dr. Nicholas Miller nm01@beremans.com